Agenus AI Stock Analysis
Agenus (AGEN) AI Stock Analysis
Agenus
(BX Swiss:AGEN)
No summary available
Agenus Business Overview & Revenue Model
Company Description
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expres...
Agenus Earnings Call Summary
The earnings call highlighted several positive developments, including strategic hires, promising BOT/BAL data, and multiple capital proposals which could strengthen the company's financial position. However, financial metrics such as a decreased cash balance and lower revenue compared to the previous year, alongside ongoing regulatory challenges, present notable challenges. The overall sentiment is cautiously optimistic as the highlights and lowlights are balanced.
Q1-2025 Updates
Positive Updates
Negative Updates
Company Guidance
During Agenus Inc.'s First Quarter 2025 Earnings Conference Call, the company outlined several strategic priorities, focusing on their innovative BOT/BAL data, operational efficiencies, and impending transactions to enhance financial strength. They aim to reduce operational cash burn to below $50 million annually by the second half of 2025. The company's financials for the first quarter showcased a cash balance of $18.5 million, a reduction from $40.4 million at the end of 2024, with a net loss of $26.4 million or $1.03 per share. Revenue was reported at $24.1 million, primarily from non-cash royalty revenue. Agenus has received four transaction proposals, including a potential Emeryville facility sale and two BOT/BAL licensing deals, aimed to bolster their balance sheet. The call emphasized the wide-reaching potential of BOT/BAL in treating cold tumors, with promising data from recent studies, and discussed the evolving regulatory landscape that could expedite therapy approvals.
Agenus Risk Analysis
Agenus disclosed 87 risk factors in its most recent earnings report. Agenus reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksAgenus Peers Comparison
Overall Rating
INO55Neutral
ONCY46Neutral
HURA45Neutral
SPRO44Neutral
TIL42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 55Neutral | $262.23M | -1.77 | -9999.00% | ― | 63.93% | 68.94% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | $46.27M | -1.22 | 664.95% | ― | ― | 11.90% | |
| 45Neutral | $87.46M | -2.71 | -146.80% | ― | ― | 24.26% | |
| 44Neutral | $55.14M | -1.92 | -75.22% | ― | 36.15% | 38.57% | |
| 42Neutral | $39.00M | -1.85 | -19.26% | ― | ― | 72.92% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| INO | Inovio Pharmaceuticals | 1.63 | -0.15 | -8.43% | |
| ONCY | Oncolytics Biotech | 0.38 | -0.66 | -63.27% | |
| HURA | Tuhura Biosciences, Inc. | 1.40 | -0.35 | -20.00% | |
| SPRO | Spero Therapeutics | 0.90 | -1.48 | -62.14% | |
| TIL | Instil Bio, Inc. | 5.40 | -6.80 | -55.74% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
